Day Two
7:50 am Coffee & Registration
8:20 am Opening Remarks
Evaluating In Vitro & Complex 3D Models for Precinical Research
8:30 am Characterization of Physiologically Relevant Ex Vivo Models
Synopsis
- Understanding pros and cons of working with patient-derived 3D tumour models
- Development of functional readouts pertinent to the selected models
- Assessment of ex vivo efficacy to immune modulators
9:00 am 3D Bioprinted Bone Mimics for Cancer Research & Drug Screening
Synopsis
- Discussing the development of these models
- Interrogating how these models can be used to study metastases and for drug screening
Unlocking Forward & Reverse Translational Studies to Revolutionise Precision Medicine
9:30 am Addressing Project Optimus: Use of Preclinical, Modelling, & Clinical Data to Identify the Optimal Dose of the PARP1-Selective Agent Saruparib for Phase 3 Studies
Synopsis
- Interrogating in vitro models to understand mechanisms of action and exposure thresholds for activity
- Analysing in vivo models to understand dose responses and exposure relationships needed for optimal efficacy
- Exploring mathematical quantitative systems pharmacology modeling to correlation of clinical exposures, PD and efficacy in relation to preclinical data and modeling
- Understanding how cross-validation of preclinical results with patient outcomes can drive more effective and personalised cancer treatments
10:00 am Morning Break & Networking
11:00 am Bedside to Bench: Interrogating Preclinical Models for Precision Oncology
Synopsis
- Exploring how precision oncology customises cancer treatment based on the genetic and molecular profiles of patients’ tumours
- Utilising mono- and co-culture patient-derived organoids (PDOs) and xenografts to help identify biomarkers for optimising regorafenib treatment in metastatic colorectal cancer
- Using paired tissue and liquid biopsies from a phase II trial, identified MIR652-3p as a biomarker and molecular driver of resistance to regorafenib
Mapping Insights with Digital Pathology & Spatial Biology to Accelerate Drug Discovery & Cell Therapy
11:30 am Leveraging Digital Pathology & AI Analytics to Drive Novel Insights into Disease Pathophysiology
Synopsis
- Utilising digital pathology and advanced analytics to enable deeper understanding of the complexity and underlying mechanisms of the tumour microenvironment
- Employing AI to analyse protein expression and decipher complex pathophysiology
12:00 pm Roundtable Discussion: Leveraging CRISPR-Cas9 for Target Discovery & Validation in Oncology
Synopsis
- In Vivo CRISPR sxreens for target identification to uncover novel oncology and immuno-oncology targets
- Advantages and disadvantages of using CRISPR for target validation
12:30 pm Lunch & Netowrking
1:30 pm Application of the Preclinical Model Pathology Workflow: From Tissue to Insight
Synopsis
- Optimizing a preclinical model pathology workflow
- Considerations for a digital pathology environment
- Application of traditional and AI-based image analysis for drug discovery
Model Validation & Characterisation to Optimise Research Efficiency & Increase Translational Impact
2:00 pm Optimising Orthotopic Bladder Cancer Models for Preclinical Testing of Intravesical Therapies
Synopsis
- Establishing orthotopic bladder xenograft models that resemble local urothelial carcinomas using a minimally invasive method
- Monitoring tumour burden with bioluminescence imaging and histologic analysis for efficacy evaluation
- Validating the approach by demonstrating a dose-dependent response upon intravesical treatment
2:30 pm Afternoon Break & Networking
3:00 pm Comparative Study to Validate Genomics Vendors
Synopsis
- Evaluating the efficacy of each technique to determine the optimal workflow
- Comparing the analysis of protein and RNA on the same slide versus separate slides to identify the best service providers
Uncovering Regulatory Insights for Successful Drug Development
3:30 pm Exploring Regulatory Ingredients in Pharmaceutical Development for Oncology Medicine
Synopsis
- Highlighting AI concepts and use in precision medicine
- Identifying biomarker concepts today and outlook
- Examining general pharmaceutical legislations in Europe and HTAR